CHA₂DS₂-VASc Score Calculator

How to Use This Calculator

1. Select each risk factor from the dropdown menus.
2. Your CHA₂DS₂-VASc score updates instantly along with annual stroke risk and anticoagulation recommendation.
3. Use the Anticoagulation Decision tab for sex-adjusted clinical score and DOAC guidance.
4. Professional tier adds HAS-BLED integration and ESC 2024 update notes.

Formula

Example

Frequently Asked Questions

• What is the CHA₂DS₂-VASc score and why is it important? ▼
  The CHA₂DS₂-VASc score is the most widely used clinical tool for estimating annual stroke risk in patients with non-valvular atrial fibrillation (AFib). It was developed by Lip et al. and published in Chest in 2010 as an improvement over the simpler CHADS₂ score, adding vascular disease, age 65-74, and female sex as additional risk factors. The acronym stands for Congestive heart failure, Hypertension, Age ≥75 (doubled), Diabetes mellitus, prior Stroke/TIA/thromboembolism (doubled), Vascular disease, Age 65-74, and Sex category (female). Scores range from 0 to 9. The score is critical because AFib is responsible for approximately 15-20% of all ischemic strokes, and these strokes tend to be more severe and disabling than strokes from other causes. By quantifying individual stroke risk, the score guides one of the most important decisions in cardiology: whether to initiate anticoagulation, which reduces stroke risk by approximately 64% but carries its own bleeding risks. Current AHA/ACC 2023 and ESC 2024 guidelines both endorse CHA₂DS₂-VASc as the primary stroke risk stratification tool for AFib.
• Who needs anticoagulation based on CHA₂DS₂-VASc? ▼
  Anticoagulation decisions are guided by the clinical CHA₂DS₂-VASc score, which excludes female sex as a standalone risk factor (sex is considered a risk modifier). Per AHA/ACC 2023 guidelines, anticoagulation is recommended (Class I) for men with a score of ≥2 and women with a score of ≥3. Anticoagulation should be considered (Class IIa) for men with a score of 1 and women with a score of 2. For men with a score of 0 or women with a score of 1 (sex being the only point), anticoagulation is generally not recommended. The ESC 2024 AFib guidelines align closely, emphasizing that a clinical score of ≥1 (excluding female sex) warrants consideration of anticoagulation in men, and ≥2 in women. DOACs (direct oral anticoagulants) such as apixaban, rivaroxaban, dabigatran, and edoxaban are strongly preferred over warfarin for non-valvular AFib because they offer similar or superior efficacy with better safety profiles, particularly for intracranial hemorrhage, and do not require routine INR monitoring.
• Why does female sex add a point to CHA₂DS₂-VASc? ▼
  Female sex was incorporated into the CHA₂DS₂-VASc score based on epidemiological data showing that women with AFib have higher absolute stroke rates than men at equivalent CHADS₂ scores, even after adjusting for other risk factors. The original 2010 derivation cohort and subsequent validation studies confirmed that female sex independently increases stroke risk in AFib patients. However, this point has been controversial and the understanding has evolved. The ESC 2024 guidelines now explicitly characterize female sex as a "risk modifier" rather than an independent stroke risk factor, meaning it should not be the sole reason to initiate anticoagulation. In practice, clinicians calculate the full CHA₂DS₂-VASc score but use the sex-excluded "clinical score" to determine whether anticoagulation is indicated: men need a clinical score ≥1 to consider therapy; women need a clinical score of ≥2. Female patients with only the sex point (score of 1 total, 0 clinical) are generally not anticoagulated. This nuanced approach reduces unnecessary anticoagulation while preserving stroke prevention in high-risk women.
• What’s the difference between CHA₂DS₂-VASc and CHADS₂? ▼
  CHADS₂ was the original AFib stroke risk score, using five factors: Congestive heart failure, Hypertension, Age ≥75, Diabetes, and prior Stroke/TIA (doubled). It scored 0-6 and was validated in multiple large cohorts, becoming widely used from the early 2000s onward. CHA₂DS₂-VASc, introduced in 2010, was developed to better classify patients who scored 0 or 1 on CHADS₂ — a group that is heterogeneous, with some truly low-risk and others at meaningful stroke risk. By adding vascular disease (prior MI, peripheral artery disease, aortic plaque), age 65-74, and female sex, CHA₂DS₂-VASc identifies a larger proportion of patients as intermediate or high risk. Studies show CHA₂DS₂-VASc outperforms CHADS₂ in identifying truly low-risk patients (those who can safely avoid anticoagulation) while also better capturing high-risk patients. Today, CHA₂DS₂-VASc has largely replaced CHADS₂ in clinical practice and international guidelines. CHADS₂ is occasionally still used in specific populations or older decision pathways, but CHA₂DS₂-VASc is now the standard of care globally.
• How is CHA₂DS₂-VASc used alongside HAS-BLED? ▼
  CHA₂DS₂-VASc quantifies stroke risk while HAS-BLED quantifies bleeding risk from anticoagulation — together they inform the net clinical benefit decision. A high HAS-BLED score (3 or more) signals that modifiable bleeding risk factors should be addressed: uncontrolled hypertension, poor INR control (if on warfarin), concurrent NSAID or antiplatelet use, and excess alcohol consumption. Critically, current guidelines emphasize that a high HAS-BLED score alone should NOT be used as a reason to withhold anticoagulation in patients with high stroke risk (CHA₂DS₂-VASc ≥2 in men). The net clinical benefit of stroke prevention typically outweighs bleeding risk in most patients with scores ≥2. Instead, a high HAS-BLED score should trigger active management of modifiable risk factors and more frequent follow-up rather than anticoagulation avoidance. The combination is used as follows: if CHA₂DS₂-VASc indicates anticoagulation is recommended AND HAS-BLED is low (0-1), proceed with anticoagulation confidently; if HAS-BLED is high (3+), optimize bleeding risks first, select the safest anticoagulant (e.g., apixaban for lowest bleeding risk), and reassess regularly.

Related Calculators